Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. The studies were closed

Omnämnda personer: Peritoneal Carcinomatoses Oncoinvent ASA.